AT466
X-Linked Myotubular Myopathy (XLMTM)
Phase 1/2Active, not recruiting
Key Facts
Indication
X-Linked Myotubular Myopathy (XLMTM)
Phase
Phase 1/2
Status
Active, not recruiting
Company
About Astellas Pharma
Astellas Pharma is a Japan-based global pharmaceutical leader with a mission to deliver transformative therapies in areas of high unmet medical need. Formed by the 2005 merger of Yamanouchi and Fujisawa, the company has grown into a $45.8 billion market cap entity with a vertically integrated model spanning R&D, manufacturing, and global commercialization. Its strategy is anchored in a patient-centric approach, a robust pipeline, and strategic external innovation to drive growth in core therapeutic areas and next-generation modalities.
View full company profile